Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/221174
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Prohens López, Rafael | - |
dc.contributor.author | Barbas Cañero, Rafael | - |
dc.contributor.author | Barceló-Oliver, Miquel | - |
dc.contributor.author | Frontera, Antonio | - |
dc.date.accessioned | 2025-05-22T10:04:06Z | - |
dc.date.available | 2025-05-22T10:04:06Z | - |
dc.date.issued | 2025-05-28 | - |
dc.identifier.issn | 1466-8033 | - |
dc.identifier.uri | https://hdl.handle.net/2445/221174 | - |
dc.description.abstract | A comprehensive combined virtual and experimental multicomponent solid-form screening has been carried out for Mirabegron, a therapeutic agent widely prescribed for interstitial cystitis and bladder pain syndrome. This systematic approach resulted in the identification and structural elucidation of three novel salt/solvate forms using single-crystal X-ray diffraction (SCXRD). These include two distinct mirabegronorotate salts (1a and 1b) and a mirabegron–isobutyrate (acetonitrile solvate) salt (2). A detailed Density Functional Theory (DFT) computational analysis unveiled a diverse array of intermolecular interactions in these newly characterized forms, some of which were not observed in the elusive crystal structure of Mirabegron previously reported in the literature. These interactions, essential for understanding the stability and properties of the solid forms, have been meticulously evaluated both structurally and energetically. Advanced computational tools, including Quantum Theory of Atoms in Molecules (QTAIM), non-covalent interaction (NCIPlot) analysis, and Molecular Electrostatic Potential (MEP) surface mapping, were employed to provide in-depth insights into the nature and strength of these interactions, further enriching the understanding of Mirabegron's solid-state chemistry. | - |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Royal Society of Chemistry | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1039/d4ce01228c | - |
dc.relation.ispartof | Crystengcomm, 2025, vol. 27, p. 2720-2728 | - |
dc.relation.uri | https://doi.org/10.1039/d4ce01228c | - |
dc.rights | cc by-nc (c) R. Prohens et al., 2025 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es/ | * |
dc.source | Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica) | - |
dc.subject.classification | Cristal·lografia | - |
dc.subject.classification | Sals | - |
dc.subject.other | Crystallography | - |
dc.subject.other | Salts | - |
dc.title | New salt-solvates of Mirabegron: a combined experimental and computational study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 758328 | - |
dc.date.updated | 2025-05-22T10:04:06Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
893338.pdf | 1.97 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License